Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Neurobiol Aging. 2014 Feb 15;35(8):1792–1800. doi: 10.1016/j.neurobiolaging.2014.02.012

Fig. 4.

Fig. 4

Intraperitoneal administration of GW4869 reduces total amyloid levels and plaque burden. (A-F) Dot plots showing soluble (A-C) and total (D-F) amyloid levels in DMSO (control)- and GW4869-treated 5XFAD mice determined by Aβ1-42 ELISA for both sexes (A, n=11 control, n=13 GW4869; D, n=13 control, n=15 GW4869), males (B,E, n=5 control, n=7 GW4869) and females (C, n=6; F, n=8). For D and E, *p < 0.05 (unpaired t-test with Welch’s correction). (G-O) Histochemical plaque data from thioflavin S-stained brain sections of 5XFAD mice treated with DMSO (control) or GW4869. Plaques per image field (G-I), total plaque area (J-L), and area per plaque (M-O) were analyzed by ImageJ for both sexes (G,J,M, n=8 control, n=9 GW4869), males (H,K,N, n=4 control, n=5 GW4869), and females (I,L,O, n=6). All data represent mean ± SEM, *p < 0.001 (unpaired t-test with Welch’s correction).